Opt In to the ALS Metabolomics Study
We believe the course of ALS can be changed in a patient if we knew where the patient was in the course of the disease.
Dr. Robert Naviaux developed an ALS Metabolomic Signature using five serum markers. We are conducting a Metabolomic Signature Study to further classify ALS patients to provide personalized and precision medicine.
​
Over 5,000 people are diagnosed annually with amyotrophic lateral sclerosis (ALS) and 330,000 people are living with the disease. You can help!
Help NDR fund novel research to bring that number to zero.
​
​
​
Neurodegeneration
ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that attacks brain and spinal cord nerve cells.
The term amyotrophic originates in the Greek language and can be translated to "There is no muscle nourishment."
When a muscle is deprived of its neural connection, it "atrophies" or deteriorates.
The term "lateral" refers to the areas of a person's spinal cord that contain portions of the nerve cells that signal and control the muscles.
As neural cells deteriorate, scarring or hardening ("sclerosis") occurs, resulting in the loss of muscle use.
While there are several drug therapies available to patients with ALS, there is currently no cure.
Unfortunately, there are currently few ALS treatments, and each takes a one-size-fits-all approach to treating symptoms.
NDR is taking a targeted, out-of-the-box approach to improving the quality of life of people who have this horrible disease.
How NDR is
Fighting ALS
NDR funded multiple avenues of research, casting a wide net to move us closer to treatments that will enhance patients' quality of life.
Understanding this information is key to treating the root causes of ALS.
​
Funding is only the beginning. NDR is unifying the efforts of ALS researchers by creating an open forum for transparency and the exchange of research findings.
We believe this will encourage new approaches to research and accelerate the development of viable treatments.
NDR's primary mission is to bring about new treatments to those suffering from neurodegenerative diseases.
​
To accomplish our mission, we work closely with researchers across the globe who share the same values: working toward a higher quality of life for patients and putting an end to ALS.
​
Your research matters to so many people. NDR wants to help move your novel research forward.
